Welcome Evening

Novel Target Identification & Early Stage Results
Wednesday 23rd October 2019

16:30

Current and Emerging Approaches for NASH Drug Development

  • Approaches developed for treating NASH and current drugs in clinical trials
  • Overview of emerging therapeutic targets
  • Key challenges into the understanding and treatment of NASH
Christine Reynet

Christine Reynet
Director
McC+R&D Consulting

16:50

CRV431, A Novel Drug Candidate for Liver Fibrosis

  • Cyclophilin inhibition attenuates many pathological mechanisms
  • CRV431 reduces fibrosis in multiple experimental models
  • CRV431 appears best suited for late stages of hepatitis of diverse etiologies
Daren Ure

Daren Ure
Director of Research & Development
ContraVir Pharmaceuticals

17:10

Small Activating RNA (saRNA) Platform for NASH/Fibrosis Targets

  • Providing data demonstrating saRNA is a clinically validated platform to upregulate target gene expression
  • Demonstrating application of saRNA platform for NASH targets and discuss liver delivery
  • Sharing new in vitro and in vivo data on HNF4a saRNA as a novel therapeutic approach for NASH
David Blakey

David Blakey
Chief Scientific Officer
MiNA Therapeutics

17:30

NKT Cells and their role in NASH as a Therapeutic Target

  • Introducing type I invariant NKT (NKT 1) cells and their role in inflammation and fibrotic disease with evidence from human studies in chronic liver disease
  • Discussing pathogenic NKT cells as a biomarker of fatty liver disease and potential to distinguish patients with advanced NASH (NAS4+) with significant fibrosis (F3+)
  • Presenting data on GRI-0621, an inhibitor of NKT 1 cells from a Phase 2a study in chronic liver disease patients and planned future studies
Marc Hertz

Marc Hertz
Chief Executive Officer
GRI Bio

17:50

Combination Therapies for NASH from the Biotech Perspective

Panel Discussion & Q&A with Preceding Speakers

18:20

Drinks Reception & Networking